Donepezil/solifenacin

Drug Profile

Donepezil/solifenacin

Alternative Names: Cognicept; CPC-201

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chase Pharmaceuticals
  • Class Antidementias; Antispasmodics; Esters; Indans; Isoquinolines; Nootropics; Piperidines; Quinuclidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Dementia

Most Recent Events

  • 28 Sep 2017 Chase Pharmaceuticals completes a phase II trial for Dementia of Alzheimer's type in USA (NCT02549196)
  • 08 Aug 2017 Chase Pharmaceuticals withdraws a phase II study prior to enrolment for Dementia of Alzheimer's type in USA (NCT02860065)
  • 01 Dec 2016 Chase Pharmaceuticals completes a phase II extension trial for Alzheimers disease in USA (NCT02434666)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top